Molecular pathogenesis of inflammatory myopathies and future therapeutic strategies. (Q36233140)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Molecular pathogenesis of inflammatory myopathies and future therapeutic strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Marinos C Dalakas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

Supplements to Clinical neurophysiology

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

288-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-β, misfolded proteins, predisposing genes, and aging

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light‐microscopic distinction from polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Inclusion body myositis: explanation for poor response to immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Cyclophosphamide in severe polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The childhood type of dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Inclusion body myositis in HIV-1 and HTLV-1 infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Current treatment of the inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Immunopathogenesis of inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Intravenous immune globulin therapy for neurologic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Molecular immunology and genetics of inflammatory muscle diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The molecular and cellular pathology of inflammatory muscle diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Muscle biopsy findings in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Neuromuscular diseases associated with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Differential expression of chemokines in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Microvascular changes in early and advanced dermatomyositis: a quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Inclusion body myositis and myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Sirolimus and cyclosporin for renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Cyclosporin in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Myositis-specific autoantibodies: overview and recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Basic principles of immunotherapy for neurologic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The immunobiology of muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Immunocytochemical and virological characteristics of hiv-associated inflammatory myopathies: Similarities with seronegative polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

High-dose intravenous human immunoglobulin in polymyositis resistant to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Total body irradiation not effective in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Treatment of dermatomyositis with intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Polymyositis in patients infected with human T-cell leukemia virus type I: the role of the virus in the cause of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The right place at the right time: novel B7 family members regulate effector T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Inclusion body myositis: no evidence for a neurogenic component

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

HTLV-1 and polymyositis in Jamaica

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The inhibition of apoptosis in myositis and in normal muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Disease progression in sporadic inclusion body myositis: observations in 78 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Expression of IFN-gamma-inducible chemokines in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

T-cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Inclusion body myositis: new concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Immune mechanisms in myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-424X%2809%2970365-4

7 January 2021

10.1016/S1567-424X(09)70365-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16106627%20AND%20SRC:MED&resulttype=core&format=json